The receptor is activated by UVA physicians will be recognized as CXCR2.

Using animal models, UVa that that CXCR2 attracts white blood cells called neutrophils in the lung, an important event in the early development of ARDS. CXCR2 has dominated in the past, but the endothelial cell effects define a new role for this receptor in the body’s physiology. ‘We can not yet say if you specifically this receptor you stop ARDS,’said Klaus Ley, director of the Cardiovascular Research Center at UVa. ‘But it makes sense to be hopeful and this type of research that could one day in the clinical use translate pursue legal action.’Ley is senior author on a paper describing the receptor CXCR2 in the 16th February 2006 ‘Online First article,’The Journal of Clinical Investigation on the Internet at..

Up to Researchers at the University of Virginia Health System have identified a molecular target , or receptor, for potential drugs for acute respiratory distress syndrome , a sudden and life-threatening failure of the lung.The results build on doc Shahabi or Paterson vaccines working, which is currently in development Advaxis. We welcome more research in the field, such as it may be significantly patented ch from Advaxis ‘ delivery platform. C. Was About Lovaxin C vaccines.. Drs Vafa Shahabi and Yvonne Paterson led a team from six leading R microbiology and published findings about the potential use of a L. Monocytogenes – based vaccine for prostate cancer . Develop developed and thereby one recombinant attenuated virus Listeria monocytogenes / PSA vaccine having potential uses to treat pCa -. The results demonstrated that Lm – LLO – PSA to for immune therapy pCa.

Thomas Moore Scientists publishing Research Listeria monocytogenes – based vaccine for Prostate Cancer in Latest Edition Of Cancer Immunology & immune therapy.

Random entries

Other entries from category "healthcare":